For U.S. healthcare professionals only

With ADYNOVATE®, your hemophilia A patient can keep building on the foundation you’ve helped them establish with the TAKEDA FVIII family.

Because There's More to Their Stories
Get the data

Indications and Limitations of Use: ADYNOVATE® [Antihemophilic factor (Recombinant), PEGylated] is a human antihemophilic factor indicated for use in children and adults with hemophilia A for the control and prevention of bleeding episodes. ADYNOVATE is not indicated for the treatment of von Willebrand disease.1

*In clinical trials, ADYNOVATE demonstrated the ability to help prevent bleeding episodes using a prophylaxis regimen.

ADYNOVATE has a simple, twice-weekly dosing schedule on the same 2 days each week, which can help personalize treatment so that your patients have more time to spend doing the other things that make them who they are.1
ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated] molecule including PEG attachment.

Designed to Extend FVIII
Circulation Time

ADYNOVATE is built on the ADVATE® [Antihemophilic Factor (Recombinant)] molecule, a proven treatment in hemophilia A patients. Created with PEGylation technology, ADYNOVATE was designed to stay in circulation longer than ADVATE, to provide factor coverage.†1-3

Proprietary PEGylation Technology exclusively licensed from Nektar Therapeutics.

Watch the MOA video
ADYNOVATE has an established and consistent safety profile across clinical studies1
Explore safety data

ADYNOVATE—a treatment that's approved in children and adults with hemophilia A1


See the data


See the results


Learn more

ADYNOVATE is not indicated for the treatment of von Willebrand Disease.

Proven bleed control

The efficacy of ADYNOVATE for prophylaxis was studied in clinical trials

Get the results